Image

VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle

VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle

Recruiting
60-85 years
All
Phase N/A

Powered by AI

Overview

The aim of this study is to investigate the effects of a four-week time-restricted eating (TRE) intervention on autophagy, immune function, and vaccine response to a seasonal influenza and COVID-19 vaccines in older healthy subjects.

Description

Aging impairs immune cell autophagy and reduces vaccine efficacy, leaving older adults highly vulnerable to influenza and other infectious diseases. Time-Restricted Eating (TRE), by limiting daily food intake to an 8-hour window without detailed calorie counting, modulates nutrient-sensing pathways (e.g., mTOR inhibition, AMPK activation) and boosts autophagic flux in preclinical models. In a randomized, controlled trial, healthy volunteers aged 60-85 will follow either four weeks of TRE or their usual eating pattern. After that, all will receive a standard seasonal vaccines against influenza and COVID-19 outside of the trial at their general practitioner (min. 2 days and max. 14 days after the stop of intervention). Blood and physiologic measurements at baseline, after four weeks of study intervention will quantify autophagy in immune cells, metabolome/proteome shifts, body composition, blood pressure, and arterial stiffness, among others. At two additional visits after the vaccination (2 weeks and 12-14 weeks after the vaccination), immune responses to the vaccination will be monitored in the blood. The investigators hypothesize that TRE-induced restoration of autophagy and amelioration of immunosenescence will correlate with stronger vaccine responses, offering a simple, low-cost strategy to rejuvenate immunity and improve preventive care in the elderly.

Eligibility

Inclusion Criteria:

  • Male and female participants, enrolled in a 1:1 ratio
  • Age 60-85 years
  • Body mass index (BMI) 20-35 kg/m²
  • Capacity to give informed consent
  • Existing health insurance to allow evaluation and treatment of any incidental findings
  • Usual daily eating window > 11 hours
  • First meal of the day before 10:00 AM
  • Willingness to receive seasonal influenza and COVID-19 vaccination and proof of scheduled appointment
  • Willingness and ability to follow a prescribed TRE dietary regimen (8-hour daily eating window; 16-hour fast without any caloric intake)
  • Appointment for simultaneous influenza and COVID-19 vaccination pre-arranged with primary care physician and coordinated with study team to align with TRE intervention

Exclusion Criteria:

  • Any vaccination (especially influenza and/or COVID-19) within 6 months before the intervention start
  • Vaccinations not related to the study, administered during the study period from V0 to V4
  • History of influenza infection within 6 months prior to initiation of the study intervention
  • History of severe adverse reactions to prior vaccinations
  • Use of pharmacological weight-loss agents (e.g., semaglutide)
  • Diabetes mellitus under ongoing pharmacological treatment
  • Symptoms of systemic inflammatory or autoimmune disease
  • Immunosuppression (including use of immunosuppressive drugs)
  • Severe hypertension (systolic > 180 mmHg or diastolic > 110 mmHg)
  • Diseases or functional disorders which, in the opinion of the study physician, preclude participation in the study
  • Participation in any fasting intervention (e.g., TRE, alternate-day fasting, 5:2, 18:6) within 6 months before enrollment
  • Participation in another diet or weight-loss program (e.g., intensive athletic training)
  • Night-shift or rotating-shift work
  • Severe, active, or unstable medical conditions requiring treatment
  • Postoperative recovery phase
  • Antibiotic therapy within 3 months before enrollment
  • Acute or chronic infections
  • Therapeutic or medically prescribed special diets
  • Vegan diet
  • Current smoker
  • Weight change > 2 kg in the month before enrollment
  • Known substance, drug, or alcohol abuse
  • Anemia
  • Claustrophobia
  • Legal incapacity or any other circumstance that prevents full understanding of the nature, importance, and implications of the study

Study details
    Vaccination
    Immunosenescence
    Metabolism

NCT07000708

Charite University, Berlin, Germany

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.